Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
December 03, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act...
Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting
November 09, 2020 08:00 ET
|
Evelo Biosciences, Inc.
-- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oral extracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- CAMBRIDGE, Mass.,...
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
October 29, 2020 07:00 ET
|
Evelo Biosciences, Inc.
-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months...
Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
October 22, 2020 16:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815
October 15, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis
October 14, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis
October 13, 2020 07:00 ET
|
Evelo Biosciences, Inc.
– Interim data expected by mid-2021 – CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of...
Evelo Biosciences Appoints Julie Carretero as Chief People Officer
September 14, 2020 07:06 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences to Participate in Upcoming Investor Conferences in September
September 08, 2020 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights
July 30, 2020 07:00 ET
|
Evelo Biosciences, Inc.
– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in...